Showing results (1201-1210 of 1,247) with videos related to

Sort By:
Pageof 125
Annals of the American Thoracic Society|June 1, 2023
Rehabilitation for People with Respiratory Disease and Frailty: An Official American Thoracic Society Workshop ReportMatthew Maddocks, Lisa J Brighton, Jennifer A Alison, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2021
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphomaS Horwitz, O A O'Connor, B Pro, et al.
Plos Pathogens|June 14, 2012
Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escapeKatharine J Bar, Chun-yen Tsao, Shilpa S Iyer, et al.
Microbiology Spectrum|November 24, 2021
SARS-CoV-2 Infection of Rhesus Macaques Treated Early with Human COVID-19 Convalescent PlasmaJesse D Deere, Timothy D Carroll, Joseph Dutra, et al.
Medrxiv : the Preprint Server for Health Sciences|March 10, 2021
Long-Term SARS-CoV-2-Specific Immune and Inflammatory Responses Across a Clinically Diverse Cohort of Individuals Recovering from COVID-19Michael J Peluso, Amelia N Deitchman, Leonel Torres, et al.
Cell Reports|August 6, 2021
Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptomsMichael J Peluso, Amelia N Deitchman, Leonel Torres, et al.
American Journal of Respiratory and Critical Care Medicine|September 16, 2022
Palliative Care Early in the Care Continuum among Patients with Serious Respiratory Illness: An Official ATS/AAHPM/HPNA/SWHPN Policy StatementDonald R Sullivan, Anand S Iyer, Susan Enguidanos, et al.
Cell Reports|June 2, 2026
An orally active dual CBP/p300 degrader targets core dependencies of multiple myelomaPraveen Kumar Tiwari, Bomin Ku, Drew A Harrison, et al.
Nature Communications|March 10, 2022
First-in-human immunoPET imaging of HIV-1 infection using <sup>89</sup>Zr-labeled VRC01 broadly neutralizing antibodyDenis R Beckford-Vera, Robert R Flavell, Youngho Seo, et al.
Plos Pathogens|June 14, 2012
Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7Nicholas F Parrish, Craig B Wilen, Lauren B Banks, et al.
Pageof 125